Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to stop breast cancer recurrence in High-Risk patients

NCT ID NCT04595565

Disease control Sponsor: GBG Forschungs GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard treatments like capecitabine or platinum chemotherapy. The study compares how long patients live without their cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sacituzumab govitecan (Trodelvy)
What this could lead to
If successful, this could offer a more effective treatment option to prevent breast cancer from returning in patients with a high risk of relapse.
What could go wrong
This is a large Phase 3 trial, but the drug may not prove better than existing options, and side effects like severe diarrhea or low blood cell counts are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,332 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements. 2. Age at diagnosis at least 18 years. 3. Willingness and ability to provide archived formalin fixed paraffin embedded tissue (FFPE) block from surgery after neoadjuvant chemotherapy and from core biopsy before start of neoadjuvant chemotherapy, which will be used for centralized prospective confirmation of HR status, HER2 status, Ki-67 and tumor-infiltrating lymphocytes (TILs) and for retrospective exploratory correlation between genes, proteins, and mRNAs relevant to sensitivity/resistance to the investigational agents. For patients with bilateral carcinoma, FFPE blocks from both sides have to be provided for central testing. 4. Histologically confirmed unilateral or bilateral primary invasive carcinoma of the breast, confirmed histologically by core biopsy. The lead tumor has to be defined by the investigator based on the inclusion criteria for the respective subtype and on the risk status. 5. Centrally confirmed HER2-negative (IHC score 0-1 or FISH negative according to ASCO/CAP guideline) and either * HR-positive (≥1% positive stained cells) disease or * HR-negative (\<1% positive stained cells) assessed preferably on tissue from postneoadjuvant residual invasive disease of the breast, or if not possible, of residual nodal invasion. If not evaluable, core of diagnostic biopsy will be used. In case of bilateral breast cancer, HER2-negative status has to be confirmed for both sides. 6. Patients with residual invasive disease after neoadjuvant chemotherapy at high risk of recurrence defined by either: * For HR-negative: any residual invasive disease \> ypT1mi and/or ypN1\>1mm * For HR-positive disease: a CPS+EG score ≥ 3 or CPS+EG score 2 and ypN+ using local ER and grade assessed on core biopsies taken before start of neoadjuvant treatment. 7. Adequate surgical treatment including resection of clinically evident disease and ipsilateral axillary lymph node dissection. SNB before NACT is discouraged. Axillary dissection before NACT is not permitted. Axillary dissection, including Targeted Axillary Dissection (TAD) should be performed according to guidelines. Histologic complete resection (R0) of all invasive and in situ tumors is required. 8. Patients must have received neoadjuvant taxane-based chemotherapy for 16 weeks (anthracyclines are permitted). This period must include 6 weeks of a taxane containing neoadjuvant chemotherapy (exception: for patients with progressive disease that occurred after at least 6 weeks of taxane-containing neoadjuvant chemotherapy, a total treatment period of less than 16 weeks is also eligible). 9. No clinical evidence for locoregional or distant relapse during or after preoperative chemotherapy. Local progression during chemotherapy is not an exclusion criterion if adequate local control could be obtained. 10. In case of local progression during neoadjuvant therapy, distant metastases must be excluded by adequate imaging (CT/MRI recommend) prior to entering the trial. 11. Immune checkpoint inhibitor / immunotherapy during (neo)adjuvant therapy is allowed until the completion of radiotherapy. 12. Patients with known gBRCA1/2 mutation without indication to adjuvant olaparib therapy are allowed to participate in the trial. 13. An interval of less than 16 weeks since the date of final surgery or less than 10 weeks from completing radiotherapy (whichever occurs last) and the date of randomization is required. 14. Radiotherapy should be delivered before the start of study treatment. Radiotherapy to the breast is indicated in all patients with breast conserving surgery and to the chest wall and lymph nodes according to local guidelines as well as in all patients with cT3/4 or ypN+ disease treated by mastectomy. 15. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 16. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedure or radiotherapy to NCI CTCAE v 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patients at the investigator´s discretion). 17. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer. 18. The patient must be accessible for scheduled visits, treatment and follow-up. 19. Normal cardiac function after neoadjuvant chemotherapy must be confirmed according to local guidelines. Results for LVEF must be above the normal limit of the institution. 20. Laboratory requirements: Hematology * Absolute neutrophil count (ANC) ≥1.5 x 109 / L * Platelets ≥100 x 109 / L * Hemoglobin ≥10 g/dL (≥6.2 mmol/L) Hepatic function * Total bilirubin \<1.25x UNL * AST and ALT ≤1.5x UNL * Alkaline phosphatase ≤2.5x UNL Renal Function * \<1.25x ULN creatinine or creatinine clearance ≥30 ml/min (according to Cockroft-Gault, if creatinine is above UNL). 21. Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential. A woman is considered to be of childbearing potential if she is not postmenopausal. Postmenopausal is defined as: * Age ≥60 years * Age \<60 years and ≥12 continuous months of amenorrhea with no identified cause other than menopause * Surgical sterilization (bilateral oophorectomy and/or hysterectomy). 22. For women of childbearing potential and males with partners of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 6 months after the last dose of sacituzumab govitecan for female patients and for at least 3 months for male patients; for at least 6 months after the last dose of capecitabine or carboplatin/cisplatin for female patients and for at least 3 months after the last dose of capecitabine or 6 months after the last dose of carboplatin/cisplatin for male patients. Examples of non-hormonal contraceptive methods with a failure rate of \< 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices. 23. Complete staging work-up prior to the initiation of neoadjuvant chemotherapy. Missing staging investigations must be performed prior to randomization. Exclusion Criteria: 1. Known hypersensitivity reaction to one of the compounds or substances used in this protocol. 2. Patients with definitive clinical or radiologic evidence of stage IV cancer (metastatic disease) are not eligible. 3. Patients with known gBRCA1/2 mutation and indicated or planned adjuvant olaparib therapy if available. 4. Patients with a history of any malignancy are ineligible with the following exceptions: * Patient has been disease-free for at least 5 years and is at low risk for recurrence of that malignancy * CIS of the cervix, basal cell and squamous cell carcinomas of the skin. 5. Female patients: pregnancy or lactation at the time of randomization or intention to become pregnant during the study and up to 6 months after sacituzumab govitecan and up to 6 months after treatment with capecitabine or carboplatin/cisplatin. 6. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study, including Gilbert´s disease, Crigler-Najjar-Syndrome, known hepatitis B, hepatitis C, known HIV positivity or known autoimmune disease other than diabetes, vitiligo, or stable thyroid disease, vitiligo, or other autoimmune skin disease with dermatologic manifestations only are permitted provided all of the following conditions are met: * Rash must cover \< 10% of body surface area * Disease is well controlled at baseline and requires only low-potency topical corticosteroids * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months. 7. Any condition that interferes with the safe administration of the treatment of physician´s choice in case the patient is randomized into the TPC arm. 8. Known or suspected congestive heart failure (\>NYHA I) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of prior infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP \>150/90 mmHg under treatment with at maximum three antihypertensive drugs), rhythm abnormalities requiring permanent treatment (excluding chronic atrial fibrillation not requiring a pacemaker), clinically significant valvular heart disease, supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;conduction abnormality requiring a pacemaker. 9. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis on chest CT scan. 10. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving chemotherapy. 11. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent. 12. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results. 13. Known allergic reactions to irinotecan. 14. Concurrent treatment with: * Chronic corticosteroids prior to study entry with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or equivalent corticosteroid.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-negative breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-negative breast cancer Triple-negative breast cancer

Contacts and locations

Locations

  • AGAPLESION Markus Krankenhaus

    Frankfurt am Main, Hesse, 60431, Germany

  • Beaumont Hospital

    Dublin, D09V2N0, Ireland

  • Breast Center KSSG

    Sankt Gallen, 9007, Switzerland

  • Brust-Zentrum Zürich

    Zurich, 8008, Switzerland

  • CH Fleyriat

    Bourg-en-Bresse, 1000, France

  • CHU Bretonneau

    Tours, 37044, France

  • CHU UCL Namur/Site Sainte Elisabeth

    Namur, 5000, Belgium

  • CHU de Limoges

    Limoges, 87042, France

  • COMPLEJO HOSPITALARIO UNIVERSITARIO A CORUÑA-Hospital Teresa Herrera (CHUAC)

    A Coruña, 15009, Spain

  • Caritasklinik St. Theresia

    Saarbrücken, Saarland, 66113, Germany

  • Centre Antoine Lacassagne

    Nice, 6189, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François Baclesse

    Caen, 14000, France

  • Centre Georges François Leclerc

    Dijon, 21000, France

  • Centre Henri Becquerel

    Rouen, 76000, France

  • Centre Hospitalier de Pau

    Pau, 64000, France

  • Centre Jean Perrin 5

    Clermont-Ferrand, 63011, France

  • Centre Leon Berard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus

    Frankfurt am Main, Hesse, 60389, Germany

  • Charité Campus Mitte, BIH Charité Rahel Hirsch

    Berlin, Brandenburg, 10117, Germany

  • Clinica Universidad de Navarra

    Madrid, 28027, Spain

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • Clinique Tivoli Ducos

    Bordeaux, 33000, France

  • Complejo Hospitalario Universitario de Albacete

    Albacete, 2006, Spain

  • Complejo Hospitalario Universitario de Santiago (Chus)

    Santiago de Compostela, 15706, Spain

  • Complejo Hospitalario de Jaén

    Jaén, 23007, Spain

  • Consorci Hospital General Universitari de Valencia

    Valencia, 46014, Spain

  • Consorci Sanitari Del Maresme

    Mataró, 08304, Spain

  • Consorcio Hospitalario Provincial de Castellón

    Castellon, 12002, Spain

  • Cork University Hospital

    Cork, T12 DFK4, Ireland

  • DIAKOVERE Henriettenstift Gynäkologie

    Hanover, Lower Saxony, 30559, Germany

  • DONAUISAR Klinikum Deggendorf

    Deggendorf, 94469, Germany

  • Elisabeth Krankenhaus

    Kassel, Hesse, 34117, Germany

  • Fundación Instituto Valenciano de Oncología

    Valencia, 46009, Spain

  • Gcs Rissa

    Sarcelles, 95200, France

  • Gemeinschaftspraxis Dallacker / Eilers

    Wolfenbüttel, Lower Saxony, 38304, Germany

  • Gemeinschaftspraxis Dres. Heinrich / Bangerter

    Augsburg, Bavaria, 86150, Germany

  • Gustave Roussy Cancer Campus

    Villejuif, 94800, France

  • HELIOS Klinikum Berlin Buch

    Berlin, 13125, Germany

  • Heinrich-Heine-Universität Düsseldorf

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Helios Klinik Wiesbaden

    Wiesbaden, Hesse, 65199, Germany

  • Helios Universitätsklinikum Wuppertal

    Wuppertal, North Rhine-Westphalia, 42283, Germany

  • Hochwaldkrankenhaus, Gesundheitszentrum Wetterau gGmbH

    Bad Nauheim, Hesse, 61231, Germany

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, 29010, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Clínico Universitario Virgen de La Arrixaca

    Murcia, 30120, Spain

  • Hospital Clínico Universitario de Valladolid

    Valladolid, 47003, Spain

  • Hospital Galdakao-Usansolo

    Galdakao, 48960, Spain

  • Hospital General Universitario Morales Meseguer

    Murcia, 3008, Spain

  • Hospital General Universitario de Alicante

    Alicante, 3010, Spain

  • Hospital Iniversitario De Toledo

    Toledo, 45007, Spain

  • Hospital Quirónsalud Sagrado Corazón

    Seville, 41013, Spain

  • Hospital San Pedro de Alcántara

    Cáceres, 10003, Spain

  • Hospital Universitari Sant Joan de Reus

    Reus, 43204, Spain

  • Hospital Universitari Son Espases

    Palma de Mallorca, 07120, Spain

  • Hospital Universitari Son Llátzer

    Palma de Mallorca, '07198, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Araba-Txagorritxu

    Vitoria-Gasteiz, 01009, Spain

  • Hospital Universitario Clinico San Cecilio

    Granada, 18016, Spain

  • Hospital Universitario Fundación Alcorcón

    Alcorcón, 28922, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Ntra.Sra. de Candelaria

    Santa Cruz de Tenerife, 38010, Spain

  • Hospital Universitario Quirónsalud Madrid

    Pozuelo de Alarcón, 28223, Spain

  • Hospital Universitario Ramón Y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario Severo Ochoa

    Leganés, 28911, Spain

  • Hospital Universitario Virgen de La Macarena

    Seville, 41009, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, 38320, Spain

  • Hospital Universitario de Cruces

    Barakaldo, Bizkaia, 48903, Spain

  • Hospital Universitario de Fuenlabrada

    Fuenlabrada, 28942, Spain

  • Hospital Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital Virgen de Los Lirios

    Alcoy, 03804, Spain

  • Hospital de La Santa Creu I Sant Pau

    Barcelona, 08041, Spain

  • Hämato-Onkologie im Medicum

    Bremen, Free Hanseatic City of Bremen, 28209, Germany

  • Hämatologie-Onkologie im Zentrum MVZ GmbH

    Augsburg, 86150, Germany

  • Hôpital Privé Des Côtes d'Armor- Centre CARIO-HPCA

    Plérin, 22190, France

  • Hôpital privé du Confluent

    Nantes, 44277, France

  • Institut Bergonié

    Bordeaux, 33000, France

  • Institut Catala D'oncologia

    Badalona, 08916, Spain

  • Institut Claudius Regaud IUCTO

    Toulouse, 31059, France

  • Institut Curie (Paris)

    Paris, 75005, France

  • Institut Godinot

    Reims, 51100, France

  • Institut Paoli-Calmettes

    Marseille, 13009, France

  • Institut Sainte Catherine

    Avignon, 84918, France

  • Institut de Cancérologie Strasbourg Europe-ICANS

    Strasbourg, 67200, France

  • Institut de cancérologie de l'ouest (Angers)

    Angers, 49055, France

  • Institut régional du Cancer de Montpellier - ICM Val d'Aurelle

    Montpellier, 34298, France

  • Johanniter Krankenhaus Genthin-Stendal

    Stendal, Saxony-Anhalt, 39576, Germany

  • Kantonsspital Graubünden

    Chur, 7000, Switzerland

  • Kliniken Essen-Mitte Evang. Huyssens-Stiftung/Knappschaft GmbH

    Essen, North Rhine-Westphalia, 45136, Germany

  • Kliniken der Stadt Köln

    Cologne, North Rhine-Westphalia, 51067, Germany

  • Klinikum Ernst von Bergmann gGmbH

    Potsdam, 14467, Germany

  • Klinikum Esslingen GmbH

    Esslingen am Neckar, Baden-Wurttemberg, 73730, Germany

  • Klinikum Kassel GmbH, Gynäkologische Ambulanz

    Kassel, Hesse, 34125, Germany

  • Klinikum Landshur GmbH

    Landshut, Bavaria, 84034, Germany

  • Klinikum Obergöltzsch Rodewisch

    Rodewisch, Saxony, 08228, Germany

  • Klinikum Oldenburg AöR

    Oldenburg, Lower Saxony, 26133, Germany

  • Klinikum Passau

    Passau, 94032, Germany

  • Klinikum Stadt Hanau

    Hanau, Hesse, 63450, Germany

  • Klinikum Südstadt

    Rostock, Mecklenburg-Vorpommern, 18059, Germany

  • Klinikum Wels-Grieskirchen GmbH

    Wels, 4600, Austria

  • Klinikum Worms

    Worms, Rhineland-Palatinate, 67550, Germany

  • Klinikum am Steinenberg

    Reutlingen, Baden-Wurttemberg, 72764, Germany

  • Klinikum der J. W. Goethe Universität

    Frankfurt am Main, Hesse, 60590, Germany

  • Knappschaft Kliniken Marienhospital Bottrop GmbH, Klinik für Gynäkologie und Geburtshilfe

    Bottrop, 46236, Germany

  • Kreiskliniken Böblingen gGmbH

    Böblingen, Baden-Wurttemberg, 71032, Germany

  • Kreiskrankenhaus Torgau

    Torgau, Saxony, 04860, Germany

  • LKH Salzburg - PMU

    Salzburg, 5020, Austria

  • Landesklinikum Wr. Neustadt

    Wiener Neustadt, 2700, Austria

  • MUG - Univ.-Klinik f. Frauenheilkunde u. Geburtshilfe Graz

    Graz, 8036, Austria

  • MUG - Univ.-Klinik f. Innere Medizin Graz

    Graz, 8036, Austria

  • MUI - Univ. Klinik f. Frauenheilkunde Innsbruck

    Innsbruck, 6020, Austria

  • MUW - AKH Wien

    Vienna, 1090, Austria

  • MUW - Med. Univ.-Klinik AKH Wien

    Vienna, 1090, Austria

  • MVZ Hämatologie-Onkologie Mayen/Koblenz GmbH

    Mayen, Rhineland-Palatinate, 56729, Germany

  • MVZ II der Niels Stensen Kliniken

    Georgsmarienhütte, Lower Saxony, 49124, Germany

  • MVZ InnMed-Filiale Traunstein

    Traunstein, Bavaria, 83278, Germany

  • MVZ Nordhausen gGmbH im Südharz Krankenhaus

    Nordhausen, Thuringia, 99734, Germany

  • MVZ für Hämatologie und Onkologie Ravensburg GmbH

    Ravensburg, 88212, Germany

  • MVZ in der Klinik Dr. Hancken

    Stade, Lower Saxony, 21680, Germany

  • Mammazentrum Hamburg

    Hamburg, Free and Hanseatic City of Hamburg, 20364, Germany

  • Marienhospital Bottrop gGmbH

    Bottrop, North Rhine-Westphalia, 46236, Germany

  • MediOnko-Institut GbR

    Berlin, State of Berlin, 10367, Germany

  • Oncologianova GmbH

    Recklinghausen, North Rhine-Westphalia, 45659, Germany

  • Onkologische Schwerpunkt- Praxis Speyer

    Speyer, Rhineland-Palatinate, 67346, Germany

  • Onkologische Schwerpunktpraxis, Studiengesellschaft Onkologie Bielefeld GbR

    Bielefeld, Nordrhein-Wastfalen, 33604, Germany

  • Ordensklinikum Linz GmbH - BHS

    Linz, 4010, Austria

  • Parc Tauli Hospital Universitari

    Sabadell, 08208, Spain

  • Praxis Dr. B. Adhami

    Erkelenz, North Rhine-Westphalia, 41812, Germany

  • Praxisklinik für Hämatologie und Onkologie

    Koblenz, Rhineland-Palatinate, 56068, Germany

  • Rotkreuzklinikum München

    München, 80634, Germany

  • SRH Wald-Klinikum Gera gGmbH, Brustzentrum Ostthüringen

    Gera, Thuringia, 07548, Germany

  • SRH Zentralklinikum Suhl

    Suhl, Thuringia, 98527, Germany

  • Salzkammergut-Klinikum Vöcklabruck

    Vöcklabruck, 4840, Austria

  • Sana Klinikum Offenbach

    Offenbach, Hesse, 63069, Germany

  • Schwarzwald-Baar-Klinikum

    Villingen-Schwenningen, Baden-Wurttemberg, 78052, Germany

  • Schwarzwald-Baar-Klinikum

    Villingen-Schwenningen, 78052, Germany

  • Schwerpunktpraxis der Gynäkologie und Onkologie

    Fürstenwalde, Brandenburg, 15517, Germany

  • Sozialstiftung Bamberg, Klinik am Bruderwald

    Bamberg, Bavaria, 96049, Germany

  • St James's Hospital

    Dublin, D08 NHY1, Ireland

  • St Vincent's University Hospital

    Dublin, D04 T6F4, Ireland

  • St, Johannes Hospital

    Dortmund, North Rhine-Westphalia, 44137, Germany

  • St. Elisabeth-Krankenhaus, Brustzentrum Köln-Hohenlind

    Cologne, North Rhine-Westphalia, 50935, Germany

  • Studien GbR Braunschweig

    Braunschweig, Lower Saxony, 38100, Germany

  • TumorZentrum Kepler Uniklinikum Linz

    Linz, 4020, Austria

  • Uniklinikum, Klinik für Geburtshilfe und Gynäkologie

    Mainz, Rhineland-Palatinate, 55131, Germany

  • University Hospital Limerick

    Limerick, V94 F858, Ireland

  • University Hospital Virgen Del Rocio S.L.

    Seville, 41013, Spain

  • University Hospital Waterford

    Waterford, X91 ER8E, Ireland

  • Universitäsklinik Halle/Saale

    Halle, Saxony-Anhalt, 06120, Germany

  • Universitätsklinik Erlangen

    Erlangen, Bavaria, 91054, Germany

  • Universitätsklinikum Aachen

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

    Dresden, Saxony, 01307, Germany

  • Universitätsklinikum Essen

    Essen, North Rhine-Westphalia, 45147, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Universitätsklinikum Mannheim, Frauenklinik

    Mannheim, Baden-Wurttemberg, 68167, Germany

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitätsklinikum St. Pölten

    Sankt Pölten, 3100, Austria

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, 89075, Germany

  • Universitätsklinikum Würzburg

    Würzburg, 97080, Germany

  • ViDia Christliche Kliniken Karlsruhe

    Karlsruhe, Baden-Wurttemberg, 76135, Germany

  • medius Kliniken gGmbH Nürtingen

    Nürtingen, Baden-Wurttemberg, 72622, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.